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Objectives The aim of this study was to describe a new familial cardiac phenotype and to elucidate the electrophysiological
mechanism responsible for the disease.
Background Mutations in several genes encoding ion channels, especially SCN5A, have emerged as the basis for a variety of
inherited cardiac arrhythmias.
Methods Three unrelated families comprising 21 individuals affected by multifocal ectopic Purkinje-related premature
contractions (MEPPC) characterized by narrow junctional and rare sinus beats competing with numerous prema-
ture ventricular contractions with right and/or left bundle branch block patterns were identified.
Results Dilated cardiomyopathy was identified in 6 patients, atrial arrhythmias were detected in 9 patients, and sudden
death was reported in 5 individuals. Invasive electrophysiological studies demonstrated that premature ventric-
ular complexes originated from the Purkinje tissue. Hydroquinidine treatment dramatically decreased the num-
ber of premature ventricular complexes. It normalized the contractile function in 2 patients. All the affected sub-
jects carried the c.665GA transition in the SCN5A gene. Patch-clamp studies of resulting p.Arg222Gln (R222Q)
Nav1.5 revealed a net gain of function of the sodium channel, leading, in silico, to incomplete repolarization in
Purkinje cells responsible for premature ventricular action potentials. In vitro and in silico studies recapitulated
the normalization of the ventricular action potentials in the presence of quinidine.
Conclusions A new SCN5A-related cardiac syndrome, MEPPC, was identified. The SCN5A mutation leads to a gain of function
of the sodium channel responsible for hyperexcitability of the fascicular-Purkinje system. The MEPPC syndrome
is responsive to hydroquinidine. (J Am Coll Cardiol 2012;60:144–56) © 2012 by the American College of
Cardiology Foundation
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July 10, 2012:144–56 MEPPC: A New SCN5A-Related Cardiac ChannelopathyPrimary arrhythmogenic disorders of the heart are a major
cause of sudden cardiac death in otherwise healthy individuals
with structurally normal hearts. Mutations in several genes
encoding ion channels and channel-interacting proteins
have emerged over the last decade as the basis for a variety
of inherited cardiac arrhythmias (1–3). Different mutations
in a single gene may account for various disorders depend-
ng on the position of the mutation, the nature of the amino
cid substituted, the type of the mutation (non-sense, false-
ense. . .), and its functional consequences (4,5).
The SCN5A gene encodes the pore-forming subunit of the
voltage-gated Na channel Nav1.5. In the heart, this channel
lays a key role in rapid impulse propagation through the
onduction system and in the excitability of atrial and ventric-
lar cardiomyocytes. Mutations in SCN5A are responsible for a
pectrum of hereditary arrhythmias, including type-3 long QT
LQT3) syndrome, the Brugada syndrome, cardiac conduction
isease, sinus node dysfunction, atrial fibrillation, and dilated
ardiomyopathy (see Tfelt-Hansen et al. [6] for a review)
5,7–13). In addition to these syndromes, originally re-
arded as independent entities, recent evidence shows con-
iderable clinical overlap, implying new disease entities
nown as overlap syndromes of the cardiac Na channel
(14).
In this article, we report a novel autosomal dominant
form of cardiac arrhythmia identified in 3 unrelated families
and characterized by multifocal ectopic Purkinje-related
premature contractions (MEPPC). This arrhythmia is due
to the c.665GA SCN5A mutation leading to a shift in
p.Arg222Gln (R222Q) Nav1.5 voltage dependency.
Methods
An expanded Methods section is available in the Online
Appendix.
Clinical evaluation. This study was in agreement with the
local guidelines for genetic research and has been approved by
the local ethical committees. Informed, written consent was
obtained from each family member who agreed to participate
to the study. Standard 12-lead electrocardiography, Holter
recording, and echocardiography were proposed to all partici-
pating family members. We also proposed electrophysiological
studies to some patients.
Patients were considered affected when ventricular ar-
rhythmia corresponding to MEPPC was detected.
Mutation analysis. Genomic DNA was extracted from
peripheral blood lymphocytes using standard protocols. The
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Amarouch contributed equally to this work. Drs. Baro´, Kyndt, and Probst contributed
equally to this work as senior authors.Manuscript received October 13, 2011; revised manuscript received January 19,
2012, accepted February 14, 2012.proband (III.1) of Family 1 was
screened for mutations in known
genes responsible for dilated car-
diomyopathy (DCM) and ar-
rhythmia, including LMNA en-
coding lamin A/C, ABCC9
encoding SUR2A, and SCN5A
(10,15,16).
Haplotype analysis. Ten mic-
rosatellite markers around the
SCN5A gene (D3S1759, D3S2432,
D3S3047, D3S3512, D3S1298, in-
tragenic SCN5A marker, D3S3521,
D3S3527,D3S3522,andD3S3559)
were genotyped. We estimated the
age of the mutation using the Genin
et al.’s method (17).
Cellularelectrophysiology. Patch-
clamp studies were performed on
COS-7 cells transiently expressing
human wild-type (WT) or R222Q
Nav1.5 (NG_008934) and human
1 subunits, using the whole-cell
configuration at room tempera-
ture (18).
Mathematical modeling. Single-
cell models of the human Pur-
kinje cells (19) and left ventricu-
lar myocytes (20) were used.
Both models were incorporated
in a multicellular model and the
propagation of the electrical
waves in the cardiac tissues was
described by a monodomain
model (21). The numerical simulations were performed on
a simplified 2D slice model described previously (22).
Statistics. All data are presented as mean  SEM. The
statistical significance of the observed effects was assessed
by the Student t test or 2-way analysis of variance
(ANOVA) followed by a Tukey test for multiple com-
parisons when needed. A p value 0.05 was considered
significant.
Results
We identified 3 families affected by the same phenotype,
segregating with an autosomal dominant pattern over 3
generations (Fig. 1A). In Family 1, 11 of 18 family members
were affected, 4 of 5 members were affected in Family 2, and
6 of 8 members were affected in Family 3. Patient charac-
teristics are summarized in Tables 1 and 2.
Clinical results. CLINICAL PHENOTYPE OF THE FAMILY 1
ROBAND (PATIENT III.1). Patient III.1 was identified at the
age of 10 years after mild dyspnea while exercising. Her
Abbreviations
and Acronyms
AF  atrial fibrillation
ANOVA  analysis of
variance
AP  action potential
DCM  dilated
cardiomyopathy
ECG  electrocardiogram
ICD  implantable
cardioverter-defibrillator
LBBB  left bundle
branch block
LQT  long QT syndrome
LVDd  left ventricular
diastolic diameter
LVEF  left ventricular
ejection fraction
MEPPC  multifocal
ectopic Purkinje-related
premature contractions
NSVT  nonsustained
ventricular tachyarrhythmia
PAC  premature atrial
complex
PVC  premature
ventricular complex
RBBB  right bundle
branch block
TTE  transthoracic
echocardiogram
VT  ventricular
tachycardia12-lead surface electrocardiogram (ECG) showed a chaotic
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Figure 1 SCN5A Mutation
(A) Pedigree and phenotype of the 3 families. Members affected with arrhythmia are indicated with a half-filled symbol. Members affected with arrhythmia and dilated cardiomy-
opathy (DCM) are indicated in black. Question marks indicate undetermined phenotype. Males and females are indicated by squares and circles, respectively. Probands are
indicated by arrows. Diagonal lines indicate the deceased individuals. Individuals carrying the mutation are indicated (). Individuals who tested negative for the mutation are
indicated (-). An implantable cardioverter-defibrillator (ICD) was implanted in 4 patients, 2 of whom also had a cardiac resynchronization therapy defibrillator (CRTD) and 1 of
whom had a DDD pacemaker (PM). Sudden death (SD) was reported in 5 individuals. (B) Mutation analysis of SCN5A revealed a heterozygous c.665GA missense mutation in
affected individual III.1 that results in a p.Arg222Gln (p.R222Q) amino acid substitution. (C) Multiple alignment analysis shows conservation of the Arg222 (R222) amino acid
among species. (D) Structure of Nav1.5. The p.Arg222Gln mutation is located in the voltage-sensing S4 segment of domain I (DI).
Clinical Data of the Family MembersTable 1 Clinical Data of the Family Members
Patient #
Age at
Diagnosis
(yrs)
Mean
Follow-Up
(yrs)
QTc
(ms)* Gender Symptoms
LVDd
(mm/m2)
LVEF Before
Medication (%)
Atrial
Arrhythmia
PVC
Morpho†
PVC
Axis
Junction
Rhythm NSVT‡
Total PVC/
24 h EPS
PVC Regression
at Exercise
Family 1
I.1 29 — — M SD — — — — — — — — No —
II.2 29 17 423 F Syncope 55 73 Paroxysmal atrial
arrhythmia
R R and L Yes No 62,000 No Yes
II.4 37 8 358 F Dyspnea 61 35 No R and L R and L Yes Yes 25,000 Yes Yes
II.6 25 20 426 F Dyspnea 48 59 No — R and L No No — No —
II.7 23 27 362 M Dyspnea, SD 60 47 No — R and L Yes No — No —
II.8 17 19 391 M Syncope 55 60 No — — No No — No —
III.1 10 7 361 F Syncope 40 32 Paroxysmal atrial
arrhythmia
R and L R and L Yes Yes 50,000 Yes Yes
III.2 0§ 5 365 F No 33 60 No — — Yes No — No —
III.6 12 9 380 M Palpitations 51 47 No R and L R and L Yes Yes 25,000 Yes Yes
III.7 17 5 360 M Dyspnea 46 67 No R and L R and L Yes No 25,000 No Yes
III.9 25 3 407 F No — — No no no Yes No 200 No —
III.11 15 3 413 M No — — No no no Yes No 11 No —
III.12 4 months — — M SD — — No — — — — — No —
Family 2
I.2 — — — F — — — — — — — — — No —
II.1 35 8 410 M Palpitations — — No — no No — — Yes —
II.3 11 0 420 M SD — — Atrial flutter — — — — — No —
III.1 6 7 405 M No 36 60 No L R and L Yes No 18,000 No Yes
III.2 12 0.5 408 M Presyncope 33 60 No L R and L Yes No 86,000 Yes Yes
Family 3
I.1 62 9 — M SD — — Atrial bigeminy R and L — Yes Yes — — —
II.2 29 26 414 F Palpitations 28 58 Paroxysmal atrial
arrhythmia
R and L R and L Yes Yes 60,000 No Yes
II.3 18 36 431 F Palpitations 28 50 Atrial fibrillation R and L R and L Yes Yes 7,134 Yes Yes
III.1 7 12 399 F Dyspnea 36 35 Paroxysmal atrial
arrhythmia
R and L R and L Yes Yes 35,650 No Yes
III.2 14 6 415 M Near collapse 31 50 Atrial flutter R and L L Yes No 17,706 Yes Yes
III.4 14 2 430 M Palpitations 29 50 Paroxysmal atrial
arrhythmia
— — Yes Yes 3,516 No —
*Bazett-corrected QT interval (QTc) measured on lead II of most recent electrocardiogram under sinus rhythm. †Premature ventricular contractions (PVCs) with right (R) and left (L) bundle branch block patterns. ‡Nonsustained ventricular tachyarrhythmia (30 s). §Gestation
of 24 weeks.
EPS  electrophysiological study; LVDd  left ventricular diastolic diameter; LVEF  left ventricular ejection fraction; SD  sudden death.
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MEPPC: A New SCN5A-Related Cardiac Channelopathy July 10, 2012:144–56cardiac rhythm comprising narrow junctional and rare sinus
beats competing with premature ventricular complexes
(PVCs) showing various right bundle branch block (RBBB)
patterns (Fig. 2A). There was an overdrive suppression of
the PVCs during treadmill exercising. Signal-averaged
ECG did not show late potentials. A Holter monitoring
device recorded more than 50,000 PVCs per 24 h. The
transthoracic echocardiogram (TTE) revealed a mild dilation
of the left ventricle (left ventricular diastolic diameter [LVDd]
54 mm or 40 mm/m2, above 97th percentile) (23), but a
ormal left ventricular ejection fraction (LVEF) (62%). She
emained asymptomatic until the age of 13 years, when she was
eferred for brief sudden loss of consciousness at rest. The
CG exhibited recurrent nonsustained ventricular tachyar-
hythmias (NSVTs) with RBBB patterns, which were con-
omitant with several fainting episodes (Fig. 2B). Several
onsustained supraventricular arrhythmias have been identified
uring the follow-up. New TTE showed a markedly enlarged
VDd (62 mm), and a decreased LVEF (32%). A dual-
hamber implantable cardioverter-defibrillator (ICD) was then
mplanted associated with oral hydroquinidine treatment.
nce the measured plasma level of the drug reached 1 mg/l
Follow-Up and Treatment of the Family MembersTable 2 Follow-Up and Treatment of the Family Members
Patient # Treatment ICD CRTD
Symptoms on
Treatment
Family 1
I.1 — No No —
II.2 Hydroquinidine Yes No No
II.4 Hydroquinidine Yes Yes No
II.6 Amiodarone No No Yes
II.7 None No No —
II.8 None No No —
III.1 Hydroquinidine Yes No No
III.2 None No No —
III.6 * No No Yes
III.7 None No No —
III.9 None No No —
III.11 None No No —
III.12 — No No —
Family 2
I.2 None No No —
II.1 Amiodarone Yes Yes Yes
II.3 — No No —
III.1 Hydroquinidine No No No
III.2 Hydroquinidine No No No
Family 3
I.1 — — — —
II.2 Flecainide No — No
II.3 Flecainide No — No
III.1 PropafeNon† DDD PM — Yes
III.2 Flecainide No — Yes
III.4 Flecainide No — No
*Flecainide, nadolol, sotalol, or verapamil. Hydroquinidine treatment and ICD implantation were pro
this drug. The patient is currently treated with propafenon, on subtherapeutic doses.
CRTD  cardiac resynchronization therapy defibrillator; DDD PM  DDD pacemaker; ICD  imp
contractions.normal range 1 to 3 mg/l), this medication succeeded in narkedly reducing the number of PVCs (Table 2). After 1 year
nder hydroquinidine treatment, the PVC burden was 1%
nd her heart was considered normal in TTE (LVDd 54 mm,
VEF 56%).
Clinical investigation of family members allowed the
dentification of 10 other affected individuals with similar
CG characteristics (Online Fig. 1).
CLINICAL PHENOTYPE OF THE FAMILY 2 PROBAND (PATIENT
III.1) AND HIS TWIN BROTHER (PATIENT III.2). Patient III.1
as identified at age 6 years because of an irregular heart
ate without any other symptoms. His twin brother was
iagnosed at 12 years with the same arrhythmia after
xperiencing syncope while cycling. A complete clinical
valuation including a TTE and magnetic resonance imag-
ng was normal, but his ECG showed frequent PVCs with
left bundle branch block (LBBB) pattern, and superior
nd inferior axial deviation (Fig. 2C). In both patients, the
olter ECG recorded tens of thousands of PVCs per
4 h (Table 1). Exercise allowed a clear decrease of their
umber. Both patients were finally treated with hydro-
uinidine, leading to a dramatic decrease of the PVC
PVC/24 h on
Medication
LVEF on (Before)
Medication (%) Sudden Death SCN5A Mutation
— — Yes —
5,000 60 (73) No Yes
5,000 50 (35) No Yes
4 — No Yes
— — Yes Yes
— — No —
5,000 56 (32) No Yes
— — No Yes
— — No Yes
— — No Yes
— — No Yes
— — No Yes
— — Yes —
— — No —
— 45 (20) No Yes
— — Yes (11) —
2,500 60 (60) No Yes
7,700 60 (60) No Yes
— — Yes (71) Yes
125 58 No Yes
5,791 50 (50) No Yes
31,894 50 (35) No Yes
486 52 (50) No Yes
21 50 (50) No Yes
but refused by the patient. †Patient III.1 started on flecainide as well, however, she did not tolerate
le cardioverter-defibrillator; LVEF  left ventricular ejection fraction; PVC  premature ventricularposedumber (Table 2).
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Figure 2 Representative ECG Tracings of the Families
(A) Representative 12-lead surface electrocardiogram (ECG) of Family 1, 10-year-old proband (Patient III.1), showing a chaotic cardiac rhythm including normal sinus and
junctional QRS complexes competing with various right bundle branch block pattern complexes corresponding to PVCs. (B) Symptomatic nonsustained ventricular tachy-
arrhythmia recorded on the same patient as in (A), at 13 years old (right bundle branch block pattern, QRS axis variation). QRS morphologies are changing from one
beat to another. (C) Twelve-lead surface ECG of Patient III.1 of Family 2 showing a chaotic cardiac rhythm with rare sinus beats and alternant junctional rhythms with
ventricular bigeminisms. Premature ventricular complexes had left bundle branch block pattern with slight variations in shape and axis.
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MEPPC: A New SCN5A-Related Cardiac Channelopathy July 10, 2012:144–56Their father and grandmother had both been affected
with DCM associated with frequent PVCs, and 1 uncle,
known as affected by atrial flutter, had died suddenly at age
11 years.
CLINICAL PHENOTYPE OF THE FAMILY 3 PROBAND
(PATIENT II.3). The index patient II.3 was identified at the
ge of 18 years during a routine medical examination. Her
2-lead ECG showed premature atrial complexes (PACs),
trial fibrillation (AF), pre-excitation on the ECG, and
requent relatively narrow PVCs with both LBBB and
BBB patterns. Electrophysiological testing revealed ecto-
ic foci from the atria, the atrioventricular junction, and the
undle branches. The accessory pathway was located at the
ight septal site. At the age of 48 years, Holter monitoring
ecorded a permanent chaotic supraventricular rhythm with
48,900 PACs and 7,000 isolated and bigeminal PVCs
35% and 5% of total QRS complexes, respectively). Fle-
ainide therapy marginally reduced ventricular ectopies;
owever, it completely suppressed supraventricular arrhyth-
ia (Holter monitoring recorded150 PACs, representing
1% of total QRS complexes). Flecainide therapy was
aintained because hydroquinidine is not available in the
etherlands, where Family 3 lives.
A REMARKABLY CONSTANT PHENOTYPE. Within these 3
amilies, 21 individuals were affected by PVCs. Patient char-
cteristics are summarized in Tables 1 and 2. Despite the
arious ages at diagnosis, from 24 weeks of gestation to 62
ears (mean age 20 years; n  20), the phenotype was
emarkably constant: narrow sinus and junctional QRS com-
lexes (n 17) competing with various complexes showing an
BBB or LBBB patterns (n  15), corresponding to PVCs
ith superior or inferior axes. We did not observe any QT
rolongation (Table 1) or ST-segment elevation.
PVCs were isolated, or paired (bigeminism) with sinus or
unctional QRS complexes. NSVTs were identified in 8
ndividuals. Five patients were affected by syncope or pre-
yncope. Sudden death was reported in one 4-month-old
oy (Patient III.12 in Family 1), an 11-year-old boy (Patient II.3
n Family 2), and 3 adult males (29, 50, and 71 years old;
atients II.7 and I.1 in Family 1 and Patient I.1 in Family
). However, PVCs were clearly identified in only 2 of these
ases (Patient II.7 in Family 1 and Patient I.1 in Family 3)
efore sudden death. Episodes of syncope or fainting during
olymorphic ventricular tachycardia (VT) episodes (Holter
r ICD monitorings) were reported in 3 females (Fig. 2B).
wo individuals in Family 1, 1 in Family 2, and 6 in Family 3
resented with atrial arrhythmia (PACs, nonsustained atrial
achyarrhythmia, or AF). One patient had AV conduction dis-
urbances. Only 1 patient in Family 3 had an accessory pathway.
ELECTROPHYSIOLOGICAL STUDY. Electrophysiological
esting was performed in 7 cases (Fig. 3, Online Fig. 2).
re-systolic potentials recorded at ectopic sites during
VCs either corresponded to Purkinje potentials during
ormal sinus beats or to the proximal extension of the left Dnterior and posterior fascicles (Figs. 3B and 3C). In all
ested patients, numerous ectopic foci were identified
long the left conduction system and its proximal exten-
ion. We did not record any PVCs from the myocardium
tself as the local ventricular electrograms were always
receded by a Purkinje potential and we did not record
ny retrograde Purkinje potential activation or slow
onduction area in the Purkinje network. Reentrant
echanisms were excluded because no PVCs or VTs
ould be pacing induced and no mid diastolic potentials
ere recorded during VT (24 –26).
When tried on Patient II.4 of Family 1, radiofrequency
pplications did not eradicate PVCs as the whole Purkinje
issue was involved in triggering PVCs from varying sites.
hereas we proposed electrophysiological studies to most
f the patients, not all of them accepted. Among affected
embers in the 3 families, PVC features were very similar
ith a sharp slope of the first ventricular deflection and close
haracteristics to authentic LBBB or RBBB patterns with
ight or left axis. In patients who underwent an electrophys-
ological study, we identified those PVC morphologies as
eing triggered from Purkinje fibers. We therefore inferred
hat similar PVC patterns may originate from similar
urkinje regions in the other patients.
EVOLUTION OF THE LEFT VENTRICULAR FUNCTION ON
ANTI-ARRHYTHMIC TREATMENT. Transthoracic echocar-
diograms were performed in all affected patients and mag-
netic resonance imaging was performed in 3 cases. Low
LVEF with dilation of the left ventricle was identified in 7
patients. Several antiarrhythmic treatments were attempted
within the families (Table 2). Amiodarone treatment was
partially successful in 2 cases (Patient II.6 in Family 1 and
Patient II.1 in Family 2). For patient II.1 in Family 2,
amiodarone and cardiac resynchronization therapy defibrillator
treatment were introduced simultaneously, partially normaliz-
ing the LVEF (from 20% to 45%). Hydroquinidine was
successful in 5 cases with a dramatic decrease in the number of
PVCs per 24 h (Table 2), and dramatically decreased the PVC
number and improved the ventricular function in all cases.
Patient III.1 was the first person to be treated by hydroquini-
dine in Family 1 and no adverse effects were noticed after 4
years of follow-up. Flecainide therapy was used in 5 patients
and greatly reduced supraventricular and ventricular arrhyth-
mias, with a clear decline in ventricular tachycardia episodes, in
3 of them. Other antiarrhythmic drugs were used in 4 patients
but were successful in 3 cases only (Table 2).
An ICD was implanted in 4 patients, 2 of which had a cardiac
resynchronization therapy defibrillator. Only 1 patient (Family 3)
had atrioventricular conduction disturbances and was implanted
with a double chamber pacemaker (Table 2).
Genetic results. MUTATION ANALYSIS. Because the first
roband identified (Family 1, Patient III.1) had DCM,
utations in LMNA encoding lamin A/C and ABCC9
ncoding SUR2A, genes reported to be associated with
CM, were searched in this patient although unsuccess-
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CM and various arrhythmogenic diseases, was also se-
uenced. Genetic testing of Family 1’s proband revealed
hat she was heterozygous for a c.665GA transition in
CN5A exon 6 (Fig. 1B), resulting in the substitution of an
rginine for a glutamine at position 222 (R222Q). This
ubstitution is located in the voltage-sensing S4 segment of
omain I of the cardiac Na channel Nav1.5 (Fig. 1D).
ubsequently, the mutation was detected in Family 2’s (Patient
II.1) and Family 3’s (Patient II.3) probands who did not
resent DCM. The mutation was 100% penetrant and
trictly segregated with the cardiac arrhythmia in all the
A
C
Figure 3 Endocardial Electroanatomic Mapping of the Left Ven
(A) Mapping of the left ventricle during sinus rhythm (Patient II.4, Family 1). Id
with a short sharp, high frequency, and low amplitude potential preceding the
sents the His bundle region, and those with pink tags represent the left anteri
ent Purkinje-related ectopic contractions (same patient as in A). Identification
yellow tags as in A. Red tags indicate sites with single short sharp, high frequ
(PVC) EGMs. Sites are labeled from 1 to 10 according to corresponding 12-lea
tified along the Purkinje network (A) or the proximal extension of the left anter
mapping from the same patient as in A. Right shows 12-lead surface ECG (25
during PVCs (local presystolic potential) reproduced a very close match to the
each lead (from 45% at V1 to 99%, mean 90%).amilies, consistent with a mutation-related disease (Fig. RA). It was absent in 600 control chromosomes. The
rg222 (R222) amino acid is highly conserved across
pecies (Fig. 1C). This mutation is reported on dbSNP
rs45546039) but at 0% in all populations and is not
eported in the National Heart, Lung, and Blood Institute
xome variant server.
HAPLOTYPE ANALYSIS. To investigate whether a common an-
estral chromosome accounted for the recurrence of the R222Q
utation in unrelated Families 1, 2, and 3, we constructed
utation-associated haplotypes by genotyping family members
or 10 microsatellite markers (Online Fig. 3, Online Appendix:
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R222Q mutation in these 3 families is very unlikely.
EFFECTS OF R222Q MUTATION ON NAV1.5 CHANNEL
FUNCTION IN COS-7 CELLS. To investigate the functional
consequences of the R222Q mutation on the Na channel
A
C
D
Figure 4 Experimental Effects of R222Q Mutation on Nav1.5 C
(A) Relative peak conductance versus membrane potential curves for Nav1.5 chan
ence of WT 1 subunit. Curves are Boltzmann fits to the data show the mutation-d
current recordings during 20-ms depolarizations to various potentials from –80 to
are 2 ms, 1,000 pA. Bold trace and arrow are Na current at –50 mV. (B) Stead
current (I/Imax) measured at –20 mV versus pre-pulse voltage. Curves show Boltzm
recordings at –20 mV after 500-ms polarization to various potentials from –110 to
cells transfected as in A. Scale bar is 2 ms. Bold trace and arrow show Na curr
dow currents (30 M TTX) obtained with a depolarizing-voltage ramp (0.5 mV/ms,
same cell (scale bar 1% Ipeak), and mean voltage at which the measured conducta
(D) Effects of quinidine on WT and R222Q Nav1.5 currents. (Left) Representative
ing potential –100 mV; frequency 0.5 Hz) in the absence (control) and presence o
condition (bottom; n  12 and 10 for WT and R222Q, respectively). (Right) Mean
ence of 30 M quinidine, of WT (thin line) and R222Q (bold line) channels and m
maximal, in each condition (at –43 mV, n  6; and at –59 mV, n  7, for WT andctivity, we used the whole-cell configuration of the patch- klamp technique (Online Appendix: Results). The presence
f the mutation did not modify the Na current density
Figs. 4A and 4B, Online Table 1). The activation curve
as shifted toward more negative potentials in the presence
f the mutation (Fig. 4A, Online Table 1). Activation
el in COS-7 Cells
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–80 mV. (C) Mean WT (n  13) and R222Q (n  14) tetrodotoxin-sensitive win-
ncy 0.5 Hz), normalized to the peak current at –20 mV (Ipeak) recorded in the
as maximal (n  12 and 14 for WT and R222Q, respectively). ***p  0.001.
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sensitivity was also changed (Fig. 4B, Online Table 1),
which, combined with the activation curve shift, predicted an
increase of the window current availability (Online Fig. 5A). The
maximum conductance of the tetrodotoxin-sensitive win-
dow current elicited by depolarizing-voltage ramps was not
significantly different in R222Q Nav1.5 expressing cells, but
the voltage at which the maximum conductance was mea-
sured was significantly shifted toward more negative values
and the window current availability was increased when
expressed as the area under the current-voltage curve (t test
p  0.001 and p  0.01, respectively) (Online Table 1,
Fig. 4C). Each of these changes caused a gain of function of
the mutant channel. However, inactivation onset kinetics
were also accelerated, causing a loss of function (Online Fig. 4B)
(2-way ANOVA p  0.001 vs. WT). Finally, kinetics of
ecovery from inactivation were not significantly modified
y the R222Q mutation (Online Fig. 4C).
In order to understand the effects of hydroquinidine
reatment on PVCs occurrence, we evaluated the WT and
222Q Na current sensitivity to quinidine, its active form.
t a concentration at which the WT peak INa was about
half-reduced (30 M in our conditions) (Online Table 2,
ig. 4D), WT and R222Q peak currents were similarly
nhibited (2-way ANOVA p  0.001 vs. control). When
uinidine was tested on the window current, the inhibition was
lso similar in both groups when measured at the maximum
onductance potential of each group (Fig. 4D, Online Table 2)
2-way ANOVA p  0.001 vs. control). Therefore, WT and
222Q Na currents were equally sensitive to quinidine.
A MULTICELLULAR COMPUTER MODEL TO CHARACTERIZE
THE MOLECULAR AND CELLULAR EVENTS LEADING TO
PREMATURE VENTRICULAR CONTRACTIONS. Because of
the multiple and opposite effects of the mutation on channel
activation and inactivation, its net effect on the action
potential (AP) is not straightforward. To get insights on
this effect, we carried out computer simulations and evalu-
ated the impact of the mutation on AP in single-cell models
of human Purkinje fibers and ventricles. Single-cell models
of Purkinje and ventricular cell AP were run in WT and
heterozygous conditions. In heterozygous conditions, in-
complete repolarization occurred in Purkinje cell AP, cor-
related with an increased late Na current (Online Fig. 6).
he ventricular AP was much less affected (Online Fig. 6).
To evaluate the possibility of a causal role of the mutation
n the generation of PVCs, we built a multicellular model
ncorporating both human cell models. In the WT condi-
ion, 1-Hz stimulation of the Purkinje fibers generated AP
hat propagated to the ventricle (Fig. 5Ba, Online Video 1A).
nterestingly, in the heterozygous condition, incomplete repo-
arization in the Purkinje fibers triggered premature APs,
ropagating into the ventricles (Fig. 5Bb, Online Video 1B).
onsistent with the disappearance of clinically observed PVCs
uring exercise, the triggered ventricular APs disappeared at
igher pacing frequencies (2 Hz) (Fig. 2B, Online Video 2B).Altogether, these results: 1) strongly suggest that the gain of
function of the Na current predominantly affects the
Purkinje cells; 2) explain the fact that the entire Purkinje
system was affected resulting in a wide variety of ectopic
foci; and 3) explain the frequency dependency of the PVCs.
Finally, the effects of quinidine were tested on the
multicellular model. Clinically relevant effects of this drug
are thought to be due to alteration of the Na current, the
transient outward current Ito (27,28), and the repolarizing
elayed rectifier current IKr (29,30). In addition, quinidine
lso inhibits Ca2 and other K currents, although in a
lower extent (31,32). Therefore, inhibition of these latter
currents was not considered. In the model, the K currents
were reduced in parallel with the heterozygous Na current.
or the first test, we chose 10 M quinidine, the maximal
therapeutic dose (i.e., preserving 50% INa, 30% IKr [33], and
0% Ito [28]). In this case, we observed a normalization of
he Purkinje and ventricular AP course at 1 Hz (not shown).
o evaluate the effects of a more “therapeutic” dose of
uinidine, we ran the model with lower current inhibition
evels. As illustrated for the ventricular AP in Figure 5B, the
ormalization was still observed when the computed quin-
dine dose was reduced to preserve 75% INa and 45% IKr and
Ito. However, when the computed quinidine dose was
urther reduced to preserve 85% INa and 50% IKr and Ito,
triggered APs reappeared. Qualitatively, if not quantita-
tively, the multicellular model mimics the cardiac response
to hydroquinidine treatment.
Discussion
We report a novel autosomal dominant form of cardiac
arrhythmia showing MEPPC. MEPPC syndrome is char-
acterized by frequent PVCs originating from various ectopic
foci along the fascicular-Purkinje system occasionally asso-
ciated with NSVTs and sudden death. Some patients (n 
9) also presented with PACs, nonsustained atrial tachyar-
rhythmias, or paroxysmal AF. In some patients, arrhythmias
were associated with mild DCM. Hydroquinidine markedly
reduced the number of PVCs and normalized the left
ventricular function in patients with DCM. We demon-
strate that a fully penetrant SCN5A gain-of-function muta-
tion is responsible for this new syndrome.
Specificity of MEPPC. Ventricular arrhythmias originating
from left ventricular fascicles have been described previously in
patients with or without structural heart disease (ischemic or
idiopathic cardiomyopathies) (24,25,34,35). Accounting for up
to 30% to 50% of arrhythmias in nonischemic DCM, bundle
branch re-entrant VTs usually have an LBBB pattern and
enlarged QRS complexes with a prolonged H-to-V interval
during sinus rhythm (34). Such conduction abnormalities were
not identified in any of our patients.
Fascicular VT is the most common form of idiopathic left
ventricular tachycardia occurring more frequently in young
males without structural heart disease and with a particular
sensitivity to verapamil (24). The ECG characteristics of
154 Laurent et al. JACC Vol. 60, No. 2, 2012
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guished from PVCs originating from the posterior papillary
muscle in the left ventricle (36) mainly by the presence of
high-frequency potentials preceding local myocardial acti-
vation suggesting that Purkinje system was involved. Idio-
pathic VTs and bundle branch VTs typically present a single
ECG morphology originating either near the posterior or
the anterior left fascicle. In our patients, ECG characteris-
tics demonstrated the varying origins of the PVCs, in either
the left or right ventricle. Electrophysiological testing using
a 3D endocardial navigation system clearly demonstrated
that the PVCs originated from more than 10 different foci
along the extension of the left anterior and posterior
fascicles. This phenomenon was responsible for important
changes in PVCs morphology (shape and axis) from one
beat to another. Similar to triggered activities, the firing was
fairly increased by isoproterenol infusion despite the in-
crease in sinus rhythm at a lesser extent. As opposed to
idiopathic fascicular VTs, which are well known to be
A
C
B
Figure 5 Effects of the R222Q Mutation on a Ventricular Cardi
(A) Dimensions of the calculation domain: Purkinje system 5  17.5 mm; ven
Simulated action potential in a distal part of the ventricle in wild-type (WT) (a)
of 1 s (B) and 0.5 s (C); and in the presence of quinidine (Bb; i.e., remaining
Also see Online Videos 1A, 1B, 2A, and 2B.highly sensitive to verapamil, this treatment had no effect onthe tested affected family members. Atrial arrhythmias were
less frequently observed than PVCs.
R222Q mutation causes the syndrome in 3 unrelated
families. Several findings support the causative role of the
R222Q SCN5A mutation in the pathogenesis of the disease in
the 3 reported families: 1) the complete cosegregation of the
mutation with the disease phenotype; 2) the identification of
the same mutation in 3 unrelated families with a remarkably
uniform phenotype; 3) the absence of the mutation in 300
ethnically matched control individuals; and 4) the high con-
servation of the R222 residue across species (Fig. 1C).
R222Q has been reported in a single patient with a
Brugada syndrome (37). With the help of Dr. Xavier
Waintraub (Hôpital Pitié-Salpêtrière, Paris, France) and
the kind permission of Dr. Pascale Guicheney (INSERM
UMR S956, Paris, France), we had the opportunity to
re-evaluate the phenotype of this patient. He was clearly not
affected by the Brugada syndrome, his ECG presenting no
ST-segment elevation in the precordial leads. His pheno-
cyte AP Obtained in the Purkinje/Ventricle Model
5  17.5 mm. Stimulation and recording sites are indicated. (B and C)
eterozygous (b) conditions with stimulation of a Purkinje cell at cycle length
eterozygous INa, 45% WT Ito and 45% WT IKr; red) at 1 Hz.omyo
tricle 3
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multifocal ventricular premature beats (57,000 thin ventric-
ular premature beats per day coming from left anterior and
posterior fascicles), atrial arrhythmias, and dilated cardio-
myopathy with moderated alteration of the ventricular
contraction (LVEF 56%) (X. Waintraub, personal commu-
nication, September 2011). His familial history found that
his mother and grandmother were also affected by DCM
associated with frequent PVCs. None of the ECGs per-
formed in patients harboring the SCN5A R222Q mutation
met the ST-segment criteria for a Brugada syndrome.
The same SCN5A mutation was also detected in a cohort
of 2,500 unrelated cases referred for LQTS genetic testing
(38). However, none of the patients from the 3 families here
presented a prolonged QTc. This may be explained by the
relatively less impaired biophysical properties of the R222Q
channel, mostly a negative shift of the window current,
when compared with that of already reported LQT3-related
mutants (5,39).
R222Q effects that we report on channel parameters were
similar to those measured by Cheng et al. (40). In addition,
we show that these effects are intermediate in the heterozy-
gous state and that they also impair the window current,
crucial during the AP plateau phase.
Looking for a mechanistic link between the genotype and
the phenotype, we simulated the effect of the mutated
channel activity on the Purkinje and ventricular electrical
activity. Two points suggest that the shift in Nav1.5 voltage
dependency is responsible for the premature ventricular
contractions originating from the fascicular-Purkinje sys-
tem. First of all, 1 of the particularities of this arrhythmia is
hat ectopic foci were observed in erratic locations of the
urkinje system, which made radiofrequency applications in-
ffective. The multicellular model shows that the impaired
unction of the Na channels, anywhere in the Purkinje
system, is sufficient enough to trigger premature APs in the
surrounding ventricular tissue. Second of all, consistent with
the disappearance of MEPPC clinically observed during exer-
cise, the triggered ventricular APs disappeared at higher pacing
frequencies.
Therefore, the model confirms the mechanism by which the
Na channel alteration is responsible for the patients’ phenotype.
Dilated cardiomyopathy is a secondary consequence of
the mutation. SCN5A R222Q mutation was already de-
tected in a few patients referred for familial or idiopathic
DCM (13,40–42). However, in all previously reported
R222Q carriers, DCM was always associated with
MEPPC-related ECG patterns. McNair et al. (13) identi-
fied 5 SCN5A mutations among 338 patients affected by
DCM (13). Among them, 2 were carriers of the R222Q
mutation and in both cases patients were affected by
frequent PVCs (1,000/h) and NSVT. Morales et al. (42)
investigated patients affected by peripartum cardiomyopathy
and identified a family carrying the R222Q mutation,
affected by DCM (42). In this family, 4 of 6 carriers were
also affected by ventricular or supraventricular tachycardia(for 1 patient no information was available). In the families
reported here, DCM was diagnosed in 6 individuals, and is
very likely a consequence of the arrhythmia, and not directly
linked to the mutation. Indeed, 13 patients affected by
MEPPC, carriers of the R222Q SCN5A mutation, were not
ffected by DCM. Most importantly, the cardiomyopathy
ecovered at least partially under antiarrhythmic treatment
fter having reduced the number of PVCs. The low pen-
trance of the associated DCM phenotype in these families
uggests that the genetic background may play a role in the
linical evolution of the disease as now admitted even for
onogenic cardiac arrhythmias (43).
Several other SCN5A mutations associated with familial
CM-arrhythmia syndrome have also been described (R814W,
1275N, T220I, and D1595H) (10–12). In these mutation
arriers, predominant clinical findings were mainly sinus brady-
ardia, atrioventricular block, atrial fibrillation, and/or atrial flutter,
henotypes quite different from the MEPPC syndrome. There-
ore, our work does not rule out that DCM may be a primary
onsequence of other SCN5A mutations.
ydroquinidine-based therapy. Because the treatment of
he affected patients with hydroquinidine has been proven to
e effective on PVCs, we investigated the effects of quini-
ine on the Na currents and observed equivalent inhibition
of WT- and R222Q Nav1.5–mediated currents. Despite the
fact that we did not consider the use dependence of
quinidine activity (44,45), the multicellular model recapit-
ulates the effects of quinidine on PVCs suppression. Alto-
gether, these results reinforce our hypothesis of MEPPC
being the primary consequence of SCN5A R222Q mutation.
Furthermore, it offers a potentially efficient therapy to limit
the symptoms for SCN5A R222Q carriers. However, it
emains to be shown that the treatment may limit the risk of
udden death.
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APPENDIX
For expanded Methods and Results sections, as well as
supplemental tables, figures, and videos, please see the online version of this
article.
